请使用支持JavaScript的浏览器!
主营:分子类,蛋白类,抗体类,生化类试剂
℡ 4000-520-616
℡ 4000-520-616
matriks/Shikari® (S-AIR TOTAL)  Anti-Infliximab biosimilar ELISA (Free/Total Ab)/INF-QNFT-REMS
产品编号:INF-QNFT-REMS
市  场 价:¥0.00
场      地:美国(厂家直采)
产品分类: 分子类>核酸酶类>其他>
联系QQ:1570468124
电话号码:4000-520-616
邮      箱: info@ebiomall.com
美  元  价:待定
品      牌: matriks
公      司:matriksbiotek
公司分类:
matriks/Shikari® (S-AIR TOTAL)  Anti-Infliximab biosimilar ELISA (Free/Total Ab)/INF-QNFT-REMS
商品介绍

Enzyme immunoassay for the semi-quantitative determination (screening) of total antibodies to infliximab biosimilar (Remsima®) in serum and plasma

SHIKARI® Semi-Quantitative Free/Total Antibodies to Infliximab Biosimilar ELISA is a sandwich assay for the determination of total and free antibodies against infliximab in serum and plasma samples. During the first incubation period, the separation of infliximab specific antibody-infliximab immune complex is provided by adding dissociation buffer. After transferring dissociation mix to the plate, infliximab antibodies are separated from infliximab in patient serum/plasma samples and they are captured by the drug infliximab coated on the wall of the microtiter wells and horse radish peroxidase (HRP) conjugated probe. After washing away the unbound components from samples, the bound enzymatic activity is detected by addition of tetramethylbenzidine (TMB) chromogen substrate. Finally, the reaction is terminated with an acidic stop solution. The intensity of the reaction colour is directly proportional to the concentration of infliximab antibodies in sample.

This kit can be also used as a semi-quantitative test for free anti-drug antibodies determination without dissociation and neutralization steps.

Remsima®, the world first biosimilar mAb (approved in 2013 by EMA). In this context, demonstration of anti-infliximab antibodies during treatment with infliximab (Remsima®) has a major concern and monitoring for the presence and/or quantitation of specific antibodies during clinical trials is an important issue for follow up of the treatment regimens. With the SHIKARI® S-AIR ELISA Kit infiliximab-specific antibodies that are bound to infiliximab in serum and can not be detected by free antibody detection kits can be determined in patients receiving Remsima®.

All SHIKARI® ELISA kits are suitable for biosimilar work.All SHIKARI® ELISA kits are produced under ISO 13485 quality system and have CE IVD mark.

For technical inquiry, please contact techsupport@matriksbiotek.com

品牌介绍

Matriks Biotek® is a biotechnology company that conducts research on biotechnology, developing products and offering its products at a global scale helping people to lead a better life.

自营商城图标
厂家直采
全球直采 正品优价
正品保障图标
正品保障
厂家直发 有线跟踪
解放采购图标
正规清关
CIF100%正规报关,提供发票
及时交付图标
及时交付
限时必达 不达必赔